Literature DB >> 24853773

C-reactive protein and lung diseases.

Marianna Agassandian1, Galina V Shurin2, Yang Ma2, Michael R Shurin3.   

Abstract

C-reactive protein (CRP), a member of the pentraxin family of plasma proteins, is one of the most distinctive acute phase reactants. In response to inflammation, cell damage or tissue injury, plasma level of CRP rapidly and dramatically increases up to 1000-fold, a phenomenon that has been used for years to monitor infections and many destructive/inflammatory conditions. The magnitude of CRP increase usually correlates with the severity of injury or inflammation and reflects an important physiological role of this interesting but still under-investigated protein. It is now generally accepted that CRP is involved in host defense and inflammation. However, the exact function of this protein in health and disease remains unclear. Many studies have demonstrated that in different pathophysiological conditions CRP might be involved in the regulation of lung function and may participate in the pathogenesis of various pulmonary disorders. The fluctuation of CRP concentrations in both alveolar fluid and serum associated with different pulmonary diseases suggests its important role in lung biology. Discussion of the still controversial functions of CRP in lung physiology and diseases is the main focus of this review.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; COPD; CRP; Inflammation; Lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24853773     DOI: 10.1016/j.biocel.2014.05.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  27 in total

Review 1.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

Review 2.  Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Authors:  Emilie Viennois; Yuan Zhao; Didier Merlin
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

3.  Chronic inflammation and risk of lung cancer in older adults in the health, aging and body composition cohort study.

Authors:  Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite
Journal:  J Geriatr Oncol       Date:  2018-08-03       Impact factor: 3.599

4.  The effect of different tobacco tar levels on DNA damage in cigarette smoking subjects.

Authors:  Congcong Zhao; Yuanchen Xie; Xiaoshan Zhou; Qiao Zhang; Na Wang
Journal:  Toxicol Res (Camb)       Date:  2020-05-20       Impact factor: 3.524

5.  Relationship between migraine headache and hematological parameters.

Authors:  Gulhan Sarıcam
Journal:  Acta Neurol Belg       Date:  2020-04-28       Impact factor: 2.396

6.  Time-dependent changes of plasma inflammatory biomarkers in type A aortic dissection patients without optimal medical management.

Authors:  Jun Gu; Jia Hu; Hong-wei Zhang; Zheng-hua Xiao; Zhi Fang; Hong Qian; Ming-hua Zhong; Ying-qiang Guo; Er-yong Zhang; Ying-kang Shi; Wei Meng
Journal:  J Cardiothorac Surg       Date:  2015-01-16       Impact factor: 1.637

7.  Inter-alpha-trypsin inhibitor heavy chain 4: a novel biomarker for environmental exposure to particulate air pollution in patients with chronic obstructive pulmonary disease.

Authors:  Kang-Yun Lee; Po-Hao Feng; Shu-Chuan Ho; Kai-Jen Chuang; Tzu-Tao Chen; Chien-Ling Su; Wen-Te Liu; Hsiao-Chi Chuang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-04-24

8.  Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial.

Authors:  Joanna C Betts; Ruth J Mayer; Ruth Tal-Singer; Linda Warnock; Chris Clayton; Stewart Bates; Bryan E Hoffman; Christopher Larminie; Dave Singh
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

Review 9.  Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs.

Authors:  Irene Ramos; Ana Fernandez-Sesma
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

10.  Proteoglycan 4 is a diagnostic biomarker for COPD.

Authors:  Kang-Yun Lee; Hsiao-Chi Chuang; Tzu-Tao Chen; Wen-Te Liu; Chien-Ling Su; Po-Hao Feng; Ling-Ling Chiang; Mauo-Ying Bien; Shu-Chuan Ho
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.